LDN-193189
|
|
|
- CAS-Nr.
- 1062368-24-4
- Englisch Name:
- LDN-193189
- Synonyma:
- LDN193189;CS-205;DM-3189;DM 3189;LDN193189(DM3189);LDN-193189, >=98%;LDN-193189 ，S2618;LDN193189 free base;LDN-193189;LDN 193189;LDN193189
LDN193189 HCl
- CBNumber:
- CB22512071
- Summenformel:
- C25H22N6
- Molgewicht:
- 406.48
- MOL-Datei:
- 1062368-24-4.mol
|
LDN-193189 Eigenschaften
- Dichte
- 1.33
- storage temp.
- Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
- L?slichkeit
- H2O: soluble5mg/mL, clear (warmed)
- Aggregatzustand
- powder
- pka
- 8.79±0.10(Predicted)
- Farbe
- yellow to orange
- Wasserl?slichkeit
- H2O: 5mg/mL, clear (warmed)
- InChI
- 1S/C25H22N6.ClH/c1-2-4-24-22(3-1)21(9-10-27-24)23-16-29-31-17-19(15-28-25(23)31)18-5-7-20(8-6-18)30-13-11-26-12-14-30;/h1-10,15-17,26H,11-14H2;1H
- InChIKey
- XHBVYDAKJHETMP-UHFFFAOYSA-N
- SMILES
- C(C=N1)(C2=CC=C(N3CCNCC3)C=C2)=CN4C1=C(C5=CC=NC6=C5C=CC=C6)C=N4.Cl
Sicherheit
- Risiko- und Sicherheitserkl?rung
- Gefahreninformationscode (GHS)
| WGK Germany |
3 |
|
|
| HS Code |
29339900 |
|
|
| Speicherklasse |
11 - Combustible Solids |
|
|
| Bildanzeige (GHS) |
|
| Alarmwort |
Warnung
|
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H302 |
Gesundheitssch?dlich bei Verschlucken. |
Akute Toxizit?t oral |
Kategorie 4 |
Warnung |
|
P264, P270, P301+P312, P330, P501 |
| H315 |
Verursacht Hautreizungen. |
Hautreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P302+P352, P321,P332+P313, P362 |
| H319 |
Verursacht schwere Augenreizung. |
Schwere Augenreizung |
Kategorie 2 |
Warnung |
|
P264, P280, P305+P351+P338,P337+P313P |
| H335 |
Kann die Atemwege reizen. |
Spezifische Zielorgan-Toxizit?t (einmalige Exposition) |
Kategorie 3 (Atemwegsreizung) |
Warnung |
|
|
|
| Sicherheit |
| P261 |
Einatmen von Staub vermeiden. |
| P305+P351+P338 |
BEI KONTAKT MIT DEN AUGEN: Einige Minuten lang behutsam mit Wasser spülen. Eventuell vorhandene Kontaktlinsen nach M?glichkeit entfernen. Weiter spülen. |
|
LDN-193189 Chemische Eigenschaften,Einsatz,Produktion Methoden
Beschreibung
Normal development and tissue repair are controlled in part by SMADs, a family of intracellular proteins that are activated by signaling
via serine/threonine kinase receptors of the TGF-
β superfamily. LDN-193189 inhibits SMAD1/5/8 phosphorylation by the bone morphogenetic protein (BMP) type I receptors, which are known as activin receptor-
like kinases (ALKs), with an IC
50 value of 4.9 nM. In
in vitro kinase assays, it shows specificity for ALK1, 2, 3, and 6 (IC
50s = 0.8, 0.8, 5.3, and 16.7 nM, respectively) over ALK4 and 5 (IC
50s = 101 and 350 nM, respectively). LDN-193189 has been used to inhibit BMP type I receptor activity to study the pathogenesis of fibrodysplasia ossificans progressive, a congenital hyperossification disorder, and to examine the role of osteogenesis in prostate tumor metastases in bone.
Verwenden
4-(6-(4-(Piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline, is a selective inhibitor of bone morphogenetic protein (BMP) pathway, useful in the treatment of diseases. Potent BMP Inhibitor, Promotes hPSC Neural Induction.
Biochem/physiol Actions
Although LDN193189 is a structural analog of dorsomorphin, these two drugs are found to establish different cellular responses. In vitro analysis reveals that LDN193189 inhibits a number of intracellular kinases such as, mitogen activated protein kinase 14 and 8 ( p38and c-Jun N-terminal kinase respectively), as well as those associated with AKT (serine/threonine kinase) and mTOR (mammalian target of rapamycin) signaling mechanisms. LDN193189 is known to elevate the levels hemoglobin and thus helps to prevent the onset of anemia of inflammation.
LDN-193189 Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
LDN-193189 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.
Global( 225)Lieferanten
1062368-24-4()Verwandte Suche:
- LDN193189
LDN193189 HCl
- 4-(6-(4-(piperazin-1-yl)phenyl)pyrazolo[1,5-a]pyrimidin-3-yl)quinoline
- LDN193189(DM3189)
- 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
- DM 3189
- DM-3189
- 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyriMidine LDN 193189(DM3189)
- 4-{6-[4-(piperazin-1-yl)phenyl]pyrazolo[
- 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline LDN 193189
- LDN 193189 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline
- 4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-quinoline hydrochloride
- LDN-193189, >=98%
- 6-(4-(2-(piperidin-1-yl)ethoxy)phenyl)-3-(pyridin-4-yl)pyrazolo[1,5-a]pyrimidine USP/EP/BP
- Quinoline, 4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-
- LDN-193189, 98%, a selective BMP signaling inhibitor
- LDN193189 free base
- CS-205
- LDN-193189;LDN 193189
- LDN-193189;LDN 193189;DM-3189;DM 3189
- LDN-193189 ，S2618
- LDN-193189（1062368-24-4）
- LDN193189
- 1062368-24-4
- C25H22N6
- Smad
- TGF-beta
- Inhibitors
- TGF-beta/Smad
